Startups
Ventus is applying structural immunology to discover and develop therapeutics targeting innate immune pathways to address human disease.
Overview
Total raised
$300M
Founded date
2019
Investors 3
| Date | Name | Website |
| Sign up to see | Sign up to see | Sign up to see |
| RA Capital Management | racap.com | |
| GV | gv.com |
Funding Rounds 3
| Date | Series | Amount | Investors |
| Sign up to see | Sign up to see | Sign up to see | Sign up to see |
| Apr 8, 2021 | Series B round | $100M | |
| May 6, 2020 | Series A round | $60M |
Mentions in press and media 7
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Feb 9, 2022 | Ventus Therapeutics Closes $140 Million Series C Financing | Ventus Therapeutics, Inc., a biopharmaceutical company utilizing structural biology and computational tools to identify and develop small molecule therapeutics across a broad range of disease indications, announced today the closing of a $1... |
| Apr 8, 2021 | Ventus Therapeutics Closes $100 Million Series B Financing | Ventus Therapeutics, Inc., a biotechnology company utilizing rational structure-based drug design to discover small-molecule medicines for high value and elusive targets, today announced a $100 million Series B financing led by RA Capital M... |
| Apr 8, 2021 | Ventus Therapeutics Raises $100M in Series B Financing | Ventus Therapeutics, Inc., a Boston, Massachusetts and Montreal, Canada-based biotechnology company utilizing rational structure-based drug design to discover small-molecule medicines for high value and elusive targets, raised $100m in Seri... |
| May 6, 2020 | Ventus Therapeutics Raises $60M in Series A Funding | Ventus Therapeutics, a Waltham, Mass. and Montreal, Canada-based a biopharmaceutical company, raised $60m in Series A financing. The round was led by founding investor Versant Ventures with participation from GV (formerly Google Ventures). ... |
| May 6, 2020 | Ventus Therapeutics Launches with $60 Million Series A | WALTHAM, Mass. & MONTREAL--(BUSINESS WIRE)--Ventus Therapeutics Inc. today announced a $60 million Series A financing led by founding investor Versant Ventures with participation by GV (formerly Google Ventures). Proceeds will be used t... |
| Ventus Therapeutics | “Ventus is applying structural immunology to discover and develop therapeutics targeting innate immune pathways to address human disease.” |
Reviews 0
FAQ about Ventus Therapeutics
When was Ventus Therapeutics founded?
Ventus Therapeutics was founded in 2019.
How much funding has Ventus Therapeutics raised?
Ventus Therapeutics has raised $300M in total across 3 funding rounds.
What funding rounds has Ventus Therapeutics raised?
Parsers VC lists 3 funding rounds of Ventus Therapeutics, among them a Series B round of $100M on Apr 8, 2021 and a Series A round of $60M on May 6, 2020.
Who has invested in Ventus Therapeutics?
Parsers VC lists 3 investors of Ventus Therapeutics, among them RA Capital Management and GV.
What has the press written about Ventus Therapeutics?
Parsers VC has collected 7 articles mentioning Ventus Therapeutics, among them “Ventus Therapeutics Closes $140 Million Series C Financing” (Feb 9, 2022) and “Ventus Therapeutics Closes $100 Million Series B Financing” (Apr 8, 2021).
Is Ventus Therapeutics still active?
Yes, Ventus Therapeutics is active; its latest activity on Parsers VC dates from Apr 18, 2023.